SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics

Schneider, Daniel J.; Lynch, Sean; Gelinas, Amy D.; Ostroff, Rachel; Rohloff, John C.; Williams, Preston P.; Janjić, Nebojša; Drolet, Daniel

doi:10.1016/b978-0-12-821595-1.00007-5

Cited by 8 publications

(6 citation statements)

References 519 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SomaScan 1,2 (spelled SOMAscan in earlier versions) is a highly multiplexed, aptamer-based assay capable of simultaneously measuring thousands of human proteins broadly ranging from femto-to micro-molar concentrations. This platform relies upon a new generation of protein-capture SOMAmer (Slow Offrate Modified Aptamer) reagents 3 .…”

Section: Introductionmentioning

confidence: 99%

Assessment of Variability in the Plasma 7k SomaScan Proteomics Assay

Candia

Daya

Tanaka

et al. 2022

Preprint

View full text Add to dashboard Cite

SomaScan is a high-throughput, aptamer-based proteomics assay designed for the simultaneous measurement of thousands of proteins with a broad range of endogenous concentrations. In its most current version, the 7k SomaScan assay v4.1 is capable of measuring 7,288 human proteins. In this work, we present an extensive technical assessment of this platform based on a study of 2,050 samples across 22 plates. Included in the study design were inter-plate technical duplicates from 102 human subjects, which allowed us to characterize different normalization procedures, evaluate assay variability by multiple analytical approaches, present signal-over-background metrics, and discuss potential specificity issues. By providing detailed performance assessments on this wide range of technical aspects, we aim for this work to serve as a valuable resource for the growing community of SomaScan users.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Variability in the Plasma 7k SomaScan Proteomics Assay

Candia

Daya

Tanaka

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…To further understand the context and findings of this study, it would be beneficial to review relevant literature and studies on thrombocytopenic purpura and similar cases, which could provide comparative insights and a broader perspective on the subject. Schneider DJ et al( 2022) [3] Table 2 highlights the challenges faced during the diagnostic process and evaluates the effectiveness of various investigative tools and techniques in addressing these challenges. Each tool's effectiveness is assessed with a rating, and notable findings are provided in the "Notes" column.…”

Section: Discussionmentioning

confidence: 99%

Diving Deep: An Exception Report On Thrombocytopenic Purpura

Nilofar,

Bose,

Palanisamy

et al. 2024

eatp

View full text Add to dashboard Cite

Thrombocytopenic purpura, commonly understood as a hematologic disorder marked by a reduction in circulating platelets, leads to pronounced bleeding and bruising, often presenting diagnostic and therapeutic challenges. This condition manifests in two primary forms: Immune Thrombocytopenic Purpura (ITP) and Thrombotic Thrombocytopenic Purpura (TTP), each with its distinct etiological pathway (Smith et al., 2019)[1]. Recent advances in the understanding of its pathophysiology suggest a multifaceted interplay between genetics, autoimmune reactions, and environmental triggers (Jones & Neunert, 2020) [2]. However, while many cases follow expected clinical trajectories, there are instances that challenge established medical paradigms. Such outliers not only test the acumen of healthcare professionals but also provide opportunities for deeper insights into the condition's varied manifestations (Brown & Aledort, 2021)[3]. This report delves into one such unusual presentation, intending to broaden our understanding of thrombocytopenic purpura and its diverse clinical spectrum.

show abstract

“…SomaScan 1,2 is a highly multiplexed, aptamer-based assay capable of simultaneously measuring thousands of human proteins broadly ranging from femto- to micro-molar concentrations. This platform relies upon a new generation of protein-capture SOMAmer ( Slow Offrate Modified Aptamer ) reagents 3 .…”

Section: The Somascan Assaymentioning

confidence: 99%

SomaScan Bioinformatics: Normalization, Quality Control, and Assessment of Pre-Analytical Variation

Candia

2024

Preprint

View full text Add to dashboard Cite

SomaScan is an aptamer-based proteomics assay designed for the simultaneous measurement of thousands of human proteins with a broad range of endogenous concentrations. In its most current version released on November 1, 2023, the 11K SomaScan assay v5.0 is capable of measuring 10,776 human proteins covering major biological processes and disease areas, including cardiology, inflammation, neurology, and oncology. Here, I review bioinformatic approaches to perform normalization, quality control, and variability assessments.

show abstract

SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics

Cited by 8 publications

References 519 publications

Assessment of Variability in the Plasma 7k SomaScan Proteomics Assay

Assessment of Variability in the Plasma 7k SomaScan Proteomics Assay

Diving Deep: An Exception Report On Thrombocytopenic Purpura

SomaScan Bioinformatics: Normalization, Quality Control, and Assessment of Pre-Analytical Variation

Contact Info

Product

Resources

About